Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity.

Rovithi, Maria

Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity. [electronic resource] - Angiogenesis 08 2017 - 287-289 p. digital

Publication Type: Letter; Review

1573-7209

10.1007/s10456-017-9555-8 doi


Angiogenesis Inhibitors--therapeutic use
Antineoplastic Agents--therapeutic use
Humans
Neoplasms--blood supply
Protein-Tyrosine Kinases--therapeutic use